fundraising News & Analysis
2 articles
Market Mood
Abivax Plans Fundraising Post-Junior Trial Data; Cash Reserves at €530M
Abivax is set to raise funds after the release of key trial data in June and is not rushing to secure a partnership or sale. The company reported cash reserves of €530 million ($613 million) as of the end of 2025. It plans to apply for FDA approval for its drug obefazimod by Q4 2023, contingent on positive trial results. Research and development expenses grew by €31.2 million to €177.8 million in 2025, indicating increased spending ahead as it prepares for a commercial launch.
Read More
Trump PAC Fundraising Includes U.S. Soldiers' Legacy and Security Briefings
Former President Trump's recent fundraising email for his political action committee (PAC) prominently features U.S. soldiers who lost their lives in the Iran war, aiming to resonate with patriotic sentiments. In addition to honoring these soldiers, the solicitation offers potential donors exclusive national security briefings, which could attract contributions from individuals interested in defense and security policies. This approach positions Trump's PAC to mobilize support amidst a polarized political landscape. The implications for markets could be significant, particularly in sectors related to defense contracting and political fundraising activities as the 2024 election cycle intensifies.
Read More